 The purpose of the Expanded Access Program is to provide oral Domperidone to patients 12 years of age where, according to the investigators judgment, a prokinetic effect is needed for the relief of refractory gastroesophageal reflux disease with upper gastrointestinal GI symptoms, gastroparesis, and chronic constipation. 